ChartRow logo
GSK
$51.15+5.03%
as of close, Nov 4, 2026
☾ AH $51.15 +5.03%
GSK plc American Depositary Shares (Each representing two Ordinary Shares)Stock · Healthcare
PeersBMYSNYPFEAMGNNVSGILD
Share this page

GSK — GSK plc American Depositary Shares (Each representing two Ordinary Shares) price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
What would $1,000 invested in GSK be worth today? →
GSK returns: By year · By month · By week · Trailing

Key stats#

Price data

Price
$51.15
YTD price return
+4.30%
YTD total return
+7.06%
Market cap
105.3B
Enterprise value
124.6B
Shares outstanding
2.1B
52W low
$45.81
52W high
$61.70
From 52W high
-17.10%
From 52W low
+11.66%
52W range
34%$45.81–$61.70
Beta
0.38

Volume

Rel volume
0.98×
30D volume
5.3M
30D $ vol
259M

Fundamentals

Sales (ttm)
43.1B
Sales/share
$20.95
EPS (ttm)
$3.66
FCF (ttm)
8.4B
FCF/share
$4.10
Book value/share
$10.71
Net margin
19.25%
ROE
37.65%
ROA
10.09%
Debt / equity
0.90×
Current ratio
0.82

Growth (CAGR, ttm) · 10Y

Sales
+7.56%+6.05%+6.66%+1.66%
Net income
+120.28%-24.45%+0.26%-4.23%
FCF
+28.14%+3.02%-2.46%+16.59%
Shares
-0.60%+0.27%+0.43%-1.70%

Per-share growth (CAGR, ttm) · 10Y

EPS
+130.66%-25.96%+0.03%-3.56%
Sales/share
+8.22%+5.77%+6.21%+3.42%
FCF/share
+28.92%+2.75%-2.88%+18.61%
Book value/share
+29.36%+19.63%+1.66%+7.12%
Dividend/share
+11.78%+4.88%-7.45%-3.33%
Price
+9.25%+14.08%+3.53%+2.82%
Total return
+13.13%+18.60%+7.81%+7.61%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
14.0×
P/OI (ttm)
10.1×
Fwd P/E
10.4×
P/S (ttm)
2.4×
P/B (mrq)
4.8×
P/FCF (ttm)
12.5×
EV/EBITDA (fy)
9.2×
EV/Sales (ttm)
2.9×
FCF yield (ttm)
8.02%
Dividend yield (fwd)Div yield
3.53%
Dividend yield (ttm)
3.55%
Dividend/share (fwd)
$1.81
Buyback yield (cash, ttm)
1.71%
Shareholder yield (cash, ttm)
4.92%

Vs own 10Y history

P/E
39th
P/OI
27th
P/S
55th
P/B
33rd
P/FCF
65th

Bar = where today’s multiple sits in GSK’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-04#

1D
+5.03%
5D
+4.94%
1M
+8.76%
3M
-0.74%
YTD
+4.30%
1Y
+9.25%
5Y
+18.95%
1D
+5.03%
5D
+4.94%
1M
+8.76%
3M
+0.16%
YTD
+7.06%
1Y
+13.12%
5Y
+45.62%

Fundamentals#

Revenue

5Y CAGR +6.7%10Y CAGR +1.7%
$43.1B FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Operating income

5Y CAGR +6.4%5Y CAGR +6.4%
$10.5B FY25
FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

EPS (diluted)

5Y CAGR +0.0%10Y CAGR −3.6%
$3.66 FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Free cash flow

5Y CAGR −2.5%10Y CAGR +16.6%
$8.4B FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

FY25: operating cash flow $10.2B, capex −$1.8B

No quarters filed for this figure.

Shares (diluted)

5Y +2.2%10Y −15.8%
2.1B FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Dividend per share

5Y CAGR −7.4%10Y CAGR −3.3%
$1.74 FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Full GSK financials →

About GSK ADR#

GSK plc ADR is an American depositary receipt representing two ordinary shares of GSK plc, a United Kingdom-based biopharmaceutical company. It provides U.S. investors with access to GSK’s healthcare business through a US-traded instrument tied to the company’s underlying ordinary shares. GSK focuses on pharmaceuticals, vaccines, and specialty medicines, with commercial activity centered on respiratory, immunology and inflammation, oncology, HIV, and infectious diseases. Its current portfolio includes products used in areas such as asthma, cancer, autoimmune disorders, and infectious disease prevention and treatment. The company operates through Commercial Operations and Research and Development, combining drug development with global commercialization of approved therapies. GSK plc ADR plays a role in the market as a widely followed healthcare security that reflects the performance of a multinational medicines and vaccines business with established reach across major therapeutic categories.

London, United Kingdom·66,841 employees·Drug Manufacturers - General·gsk.com·As of Oct 28, 2026

Recent filings#

No earnings release, press release or insider trade outside a 10b5-1 plan in the last 120 days.

All filings and insider trades →
TickerName1M1D
LLYEli Lilly and Company+24.07%+0.61%
JNJJohnson & Johnson+7.92%+3.81%
ABBVAbbVie Inc.+12.18%+3.09%
MRKMerck & Co. Inc.+4.20%+3.93%
UNHUnitedHealth Group Incorporated Common Stock (DE)+10.08%+1.22%
NVSNovartis AG+17.01%+3.59%
TMOThermo Fisher Scientific Inc.+7.84%+1.12%
AMGNAmgen Inc.+18.69%+3.71%